United Therapeutics Corporation
UTHR
$301.42
-$6.58-2.14%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 7.95% | -1.74% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.95% | -1.74% | |||
| Cost of Revenue | 21.87% | -8.66% | |||
| Gross Profit | 6.35% | -0.87% | |||
| SG&A Expenses | 3.53% | 6.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.79% | 9.77% | |||
| Operating Income | 6.05% | -11.34% | |||
| Income Before Tax | 6.81% | 2.03% | |||
| Income Tax Expenses | 6.41% | 19.75% | |||
| Earnings from Continuing Operations | 6.94% | -2.52% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.94% | -2.52% | |||
| EBIT | 6.05% | -11.34% | |||
| EBITDA | 5.77% | -10.70% | |||
| EPS Basic | 6.46% | -2.74% | |||
| Normalized Basic EPS | 6.03% | -10.85% | |||
| EPS Diluted | 7.20% | -3.22% | |||
| Normalized Diluted EPS | 6.73% | -11.20% | |||
| Average Basic Shares Outstanding | 0.45% | 0.22% | |||
| Average Diluted Shares Outstanding | -0.21% | 0.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||